Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: I am still a believer in the Icarus myth and the danger of dramatic upside flight on low volume wings

April 20, 2022 7:35am

Don't get too excited by one good day

Pre-open indications: 3 Upside Indications, 2 SELL into Strength, 6 Downside Indications and 1 Pimp/Pump/Promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Just the facts … I ask questions and note the indications of what could happen …

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

Dow futures are UP +0.17% (+59 points), S&P futures are UP +0.02% (+1 points) and NASDAQ futures are DOWN -0.20% (-29 points) early in the pre-open

Stock futures were mixed suggesting some weakness in Wednesday pre-open as big corporate and non-sector earnings continue,

European markets were positive although focused on the “second phase” of the war in Ukraine while the IMF cut its global growth projections for 2022 and 2023,

Asia-Pacific markets were mixed as China defied expectations by keeping its benchmark lending rate unchanged while Japan and Australia climbed.

Henry’omics:

All the major averages saw strong gains on Tuesday, posting their best day since March 16.

Yesterday, the Dow closed UP +499.51 points (+1.45%); the S&P closed UP +70.52 points (+1.61%) while the Nasdaq closed UP +287.30 points (+2.15%)

The stock market rally showed some fight Tuesday. The S&P 500 moved back above its 50-day line and its 21-day exponential moving average. The Dow rebounded from its 50-day toward its 200-day. The Nasdaq rallied back near its 50-day and also got above its 50-day almost reclaiming its 200-day. <IBD>

Last night’s RegMed Investors’ (RMi) closing bell post: “the cell and gene therapy sector’s ascension. Love the upside with a revolving door to the upside, how soon will we be flirting with bottoms again?” … https://www.regmedinvestors.com/articles/12395

Ebb and flow –

Q2/22 – 1 holiday, 4 positive and 8 negative close

Q1/22:

· March – 13 negative and 10 positive closes

· February stats: 11 negative, 8 positive closes and 1 holiday

· January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Upside Indications:

CRISPR Therapeutics (CRSP) closed up +$0.22 to $58.96 with a positive +$1.04 or +1.76% pre-open indication,

Pluristem (PSTI) closed up +$0.08 to $1.84 with a positive +$0.06 or +3.26% pre-open indication,

uniQure NV (QURE) closed up +40.21 to $17.53 after Monday’s -$1.43 with a positive +$0.87 or +4.96% pre-open indication.

SELL into Strength:

Verastem (VSTM) closed down -$0.17 to $1.66 with a positive +$0.06 or +3.61% pre-open indication,

Vericel (VCEL) closed up +$2.19 to $37.35 after Monday’s -$1.60 to $35.16 with a neutral pre-open indication,

Downside Indications:

Beam Therapeutics (BEAM) closed up +$0.72 after Monday’s -$2.42 with a negative -$1.10 or -2.46% pre-open indication,

Editas Medicine (EDIT) closed up+$0.07 to $15.78 with a negative -$0.13 or -0.82% pre-open indication,

Intellia Therapeutics (NTLA) closed up +$0.42 to $57.04 with a negative -$0.15 or -0.26% pre-open indication,

Ionis Pharmaceuticals (IONS) closed down -$0.05 to $40.96 with a negative -$0.43 or -1.05% pre-open indication,

Ultragenyx (RARE) closed down -$0.34 to $78.10 with a negative -$3.10 or -3.97% pre-open indication,

Voyager therapeutics (VYGR) closed up +$0.53 to $9.54 with a negative -$0.13 or -1.36% pre-open indication,

Pimp/Pump and Promote:

Biostage (BSTG) closed up +$0.48 with 1,168 shares traded after Monday -$0.48 with 2,873 shares traded after Thursday’s -$0.02 to $5.98 and last Wednesday ’s +$0.50 with 2,851 shares traded.

WARNING: WHY BUY this equity with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a precarious financial position dependent on a possible cash infusion? Also, WHY the pump of the volume to gain share appreciation – they have to reverse the multiple private placements (the priciest was $4.71) for a potential/proposed stock offering.

The BOTTOM LINE: The cell and gene therapy sector’s rally remains seems under pressure.

Investors should keep share pricing upside as exposure to upcoming declines.

I reiterate and I ”State the obvious, investors are NOT in control of daily market driven sector appreciation or downward dives.

I try to keep it simple … and short!

To expect a payday; volatility and low volume are part of the equation which could set-up BUY/SELL opportunities.

I am still, in the here and now, the cell and gene therapy sector will be fluttering; we are about to enter the earnings’ zone!

Earnings’ season is upon us as Alnylam Pharmaceuticals (ALNY) reports Thursday,4/28 followed so far by Sage Therapeutics (SAGE) on 5/3 and AxoGen (AXGN) on 5/4.

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

Share pricing intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.